A Phase II study of T-4288 in patients with community-acquired pneumonia
Phase 2
- Conditions
- Community-acquired pneumonia
- Registration Number
- JPRN-jRCT2080222672
- Lead Sponsor
- Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Age: 20 years of age and older
2. Gender : Both
3. Confirmed clear infiltrative shadow by chest X-ray or CT within 48 hours prior to the first administration of the study drug
4. Confirmed at least one of the following changes in laboratory values;
-WBC increased (WBC > 10000 /mm3)
-Stab cell > 15%
-WBC decreased (WBC < 4500 /mm3)
5. Confirmed at least one of the following clinical symptoms and/or findings:
-Cough
-Abnormal findings on auscultation and/or percussion
-Dyspnea or tachypnea
-Hypoxemia
6. Others
Exclusion Criteria
1. Having improvement of clinical symptoms due to pneumonia by other systemic antibiotics
2. Having a history of allergy to macrolide or quinolone antibiotics
3. Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method